{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.3","upperLimit":"7.05","value":"4.17"},{"groupId":"OG001","lowerLimit":"4.79","upperLimit":"10.53","value":"7.66"},{"groupId":"OG002","lowerLimit":"3.97","upperLimit":"9.88","value":"6.93"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"333"},{"groupId":"OG001","value":"323"},{"groupId":"OG002","value":"321"}],"units":"Participants"}],"title":"Change at Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.46","upperLimit":"8.2","value":"5.33"},{"groupId":"OG001","lowerLimit":"4.28","upperLimit":"10.01","value":"7.15"},{"groupId":"OG002","lowerLimit":"2.32","upperLimit":"8.24","value":"5.28"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"339"},{"groupId":"OG001","value":"339"},{"groupId":"OG002","value":"323"}],"units":"Participants"}],"title":"Change at Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.06","upperLimit":"7.82","value":"4.94"},{"groupId":"OG001","lowerLimit":"3.93","upperLimit":"9.66","value":"6.79"},{"groupId":"OG002","lowerLimit":"1.64","upperLimit":"7.58","value":"4.61"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"330"},{"groupId":"OG001","value":"332"},{"groupId":"OG002","value":"316"}],"units":"Participants"}],"title":"Change at Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.17","upperLimit":"6.96","value":"4.07"},{"groupId":"OG001","lowerLimit":"2.35","upperLimit":"8.09","value":"5.22"},{"groupId":"OG002","lowerLimit":"1.03","upperLimit":"6.99","value":"4.01"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"316"},{"groupId":"OG001","value":"323"},{"groupId":"OG002","value":"302"}],"units":"Participants"}],"title":"Change at Cycle 4"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.44","upperLimit":"7.27","value":"4.36"},{"groupId":"OG001","lowerLimit":"2.26","upperLimit":"8.06","value":"5.16"},{"groupId":"OG002","lowerLimit":"1.09","upperLimit":"7.08","value":"4.09"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"293"},{"groupId":"OG001","value":"290"},{"groupId":"OG002","value":"283"}],"units":"Participants"}],"title":"Change at Cycle 5"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.53","upperLimit":"6.39","value":"3.46"},{"groupId":"OG001","lowerLimit":"0.88","upperLimit":"6.73","value":"3.8"},{"groupId":"OG002","lowerLimit":"0.35","upperLimit":"6.39","value":"3.37"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"272"},{"groupId":"OG001","value":"267"},{"groupId":"OG002","value":"262"}],"units":"Participants"}],"title":"Change at Cycle 6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.2","upperLimit":"6.12","value":"3.16"},{"groupId":"OG001","lowerLimit":"0.71","upperLimit":"6.61","value":"3.66"},{"groupId":"OG002","lowerLimit":"0.38","upperLimit":"6.45","value":"3.42"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"246"},{"groupId":"OG002","value":"241"}],"units":"Participants"}],"title":"Change at Cycle 7"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.37","upperLimit":"5.59","value":"2.61"},{"groupId":"OG001","lowerLimit":"-0.27","upperLimit":"5.68","value":"2.71"},{"groupId":"OG002","lowerLimit":"-1.39","upperLimit":"4.73","value":"1.67"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"228"},{"groupId":"OG001","value":"222"},{"groupId":"OG002","value":"225"}],"units":"Participants"}],"title":"Change at Cycle 8"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.87","upperLimit":"5.27","value":"2.2"},{"groupId":"OG001","lowerLimit":"-0.35","upperLimit":"5.68","value":"2.67"},{"groupId":"OG002","lowerLimit":"-1.22","upperLimit":"5.01","value":"1.89"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"174"},{"groupId":"OG001","value":"196"},{"groupId":"OG002","value":"190"}],"units":"Participants"}],"title":"Change at Cycle 9"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-1.05","upperLimit":"5.21","value":"2.08"},{"groupId":"OG001","lowerLimit":"-0.99","upperLimit":"5.18","value":"2.09"},{"groupId":"OG002","lowerLimit":"-1.32","upperLimit":"5","value":"1.84"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"164"},{"groupId":"OG002","value":"166"}],"units":"Participants"}],"title":"Change at Cycle 10"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-3.18","upperLimit":"3.47","value":"0.15"},{"groupId":"OG001","lowerLimit":"0.1","upperLimit":"6.6","value":"3.35"},{"groupId":"OG002","lowerLimit":"-0.67","upperLimit":"6.02","value":"2.68"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"115"},{"groupId":"OG002","value":"111"}],"units":"Participants"}],"title":"Change at Cycle 11"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-2.94","upperLimit":"3.97","value":"0.52"},{"groupId":"OG001","lowerLimit":"0.61","upperLimit":"7.29","value":"3.95"},{"groupId":"OG002","lowerLimit":"-2.78","upperLimit":"4.05","value":"0.63"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"98"}],"units":"Participants"}],"title":"Change at Cycle 12"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-1.94","upperLimit":"5.53","value":"1.79"},{"groupId":"OG001","lowerLimit":"-0.95","upperLimit":"5.91","value":"2.48"},{"groupId":"OG002","lowerLimit":"-3","upperLimit":"4.09","value":"0.55"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"85"},{"groupId":"OG002","value":"80"}],"units":"Participants"}],"title":"Change at Cycle 13"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-5.56","upperLimit":"2","value":"-1.78"},{"groupId":"OG001","lowerLimit":"-1.29","upperLimit":"5.69","value":"2.2"},{"groupId":"OG002","lowerLimit":"-4.06","upperLimit":"3.21","value":"-0.42"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"78"},{"groupId":"OG002","value":"71"}],"units":"Participants"}],"title":"Change at Cycle 14"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-7.5","upperLimit":"0.51","value":"-3.49"},{"groupId":"OG001","lowerLimit":"-1.82","upperLimit":"5.3","value":"1.74"},{"groupId":"OG002","lowerLimit":"-2.51","upperLimit":"4.95","value":"1.22"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"71"},{"groupId":"OG002","value":"63"}],"units":"Participants"}],"title":"Change at Cycle 15"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-7.89","upperLimit":"0.23","value":"-3.83"},{"groupId":"OG001","lowerLimit":"-2.11","upperLimit":"5.35","value":"1.62"},{"groupId":"OG002","lowerLimit":"-3.3","upperLimit":"4.3","value":"0.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"58"},{"groupId":"OG002","value":"58"}],"units":"Participants"}],"title":"Change at Cycle 16"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-4.15","upperLimit":"1.99","value":"-1.08"},{"groupId":"OG001","lowerLimit":"-4.48","upperLimit":"1.59","value":"-1.45"},{"groupId":"OG002","lowerLimit":"-4.97","upperLimit":"1.32","value":"-1.82"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"176"},{"groupId":"OG001","value":"185"},{"groupId":"OG002","value":"175"}],"units":"Participants"}],"title":"Change at Follow-up 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-3.16","upperLimit":"3.13","value":"-0.02"},{"groupId":"OG001","lowerLimit":"-5.17","upperLimit":"1.21","value":"-1.98"},{"groupId":"OG002","lowerLimit":"-5.04","upperLimit":"1.47","value":"-1.78"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"145"},{"groupId":"OG001","value":"129"},{"groupId":"OG002","value":"133"}],"units":"Participants"}],"title":"Change at Follow-up 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-3.83","upperLimit":"2.74","value":"-0.55"},{"groupId":"OG001","lowerLimit":"-5.47","upperLimit":"1.14","value":"-2.16"},{"groupId":"OG002","lowerLimit":"-6.08","upperLimit":"0.72","value":"-2.68"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"103"},{"groupId":"OG002","value":"101"}],"units":"Participants"}],"title":"Change at Follow-up 3"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-4.61","upperLimit":"2.23","value":"-1.19"},{"groupId":"OG001","lowerLimit":"-7.18","upperLimit":"-0.1","value":"-3.64"},{"groupId":"OG002","lowerLimit":"-5.25","upperLimit":"1.84","value":"-1.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"81"}],"units":"Participants"}],"title":"Change at Follow-up 4"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-5.61","upperLimit":"1.51","value":"-2.05"},{"groupId":"OG001","lowerLimit":"-10.39","upperLimit":"-3.06","value":"-6.73"},{"groupId":"OG002","lowerLimit":"-4.18","upperLimit":"2.99","value":"-0.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"63"},{"groupId":"OG002","value":"76"}],"units":"Participants"}],"title":"Change at Follow-up 5"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-4.92","upperLimit":"2.58","value":"-1.17"},{"groupId":"OG001","lowerLimit":"-9.32","upperLimit":"-1.4","value":"-5.36"},{"groupId":"OG002","lowerLimit":"-7.87","upperLimit":"-0.23","value":"-4.05"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"46"},{"groupId":"OG002","value":"57"}],"units":"Participants"}],"title":"Change at Follow-up 6"}],"denoms":[{"counts":[{"groupId":"OG000","value":"375"},{"groupId":"OG001","value":"370"},{"groupId":"OG002","value":"361"}],"units":"Participants"}],"description":"FACT-P was a 39-item participant rated questionnaire that measures the concerns of participants with prostate cancer. It consisted of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate-specific concerns (12 items). FACT-P total score was the sum of all 5 subscale scores. It ranged from 0 to156 with higher score indicated better quality of life with fewer symptoms.","dispersionType":"95% Confidence Interval","groups":[{"description":"Docetaxel (TXT) 75 mg/m\\^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.","id":"OG000","title":"Docetaxel 75 mg/m^2"},{"description":"Cabazitaxel 20 mg/m\\^2 IV infusion on Day 1 of each 21 -day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.","id":"OG001","title":"Cabazitaxel 20 mg/m^2"},{"description":"Cabazitaxel 25 mg/m\\^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.","id":"OG002","title":"Cabazitaxel 25 mg/m^2"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"Analysis was performed on FACT-P population that included all participants with evaluable individual FACT-P subscale score at baseline and post-baseline on at least 1 of the subscale domains. Here, 'number analyzed' = participants with available data for each specified category.","reportingStatus":"POSTED","timeFrame":"Baseline, Day 1 of each cycle 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 (each cycle 21-day); post-treatment follow up 1, 2, 3, 4, 5, 6 (each up to 12 weeks)","title":"Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P) Total Score as a Measure of Health Related Quality of Life (HRQoL)","type":"SECONDARY","unitOfMeasure":"units on a scale"}